Ropinirole

Ropinirole belongs to the non-ergoline class of dopamine agonists, a group of Parkinson's drugs that, unlike the older ergot-derived agents, are not chemically related to ergot alkaloids. It acts chiefly at the D2 and D3 subtypes of the dopamine receptor, with especially high affinity for D3 receptors ^[1]. By stimulating these receptors directly, it substitutes for some of the dopamine signaling that is lost in Parkinson's disease ^[1].

The compound was developed under the research code SK&F-101468 and was first described in the scientific literature in the 1980s. It received United States approval in 1997 and is a prescription-only medicine, now widely available as a generic and marketed under names such as Requip ^[1]. It is supplied both as a standard tablet and as a once-daily prolonged-release tablet.

Ropinirole has two main uses. In Parkinson's disease it is given to ease the tremor, stiffness, and slowed movement of the condition, either on its own in earlier disease or together with levodopa as the illness advances ^[1]. In restless legs syndrome it is taken in much smaller amounts than are used for Parkinson's disease, where it can reduce the uncomfortable urge to move the legs and improve sleep ^[1]. Long-term dopamine agonist treatment for restless legs syndrome, however, carries a well-recognized problem called augmentation, in which symptoms gradually worsen and spread over time, sometimes prompting unhelpful dose increases, so these drugs are now used more cautiously in that setting ^[2][3].

Ropinirole is taken orally. Immediate-release tablets are usually divided through the day, while a prolonged-release form releases the drug steadily over a full day. Because the body clears it within a few hours, the immediate-release version requires regular dosing to maintain its effect ^[1].

Ropinirole is prescription only. Common effects are nausea, dizziness, drowsiness and low blood pressure on standing, and it can cause sudden sleep attacks, so driving needs caution until you know how it affects you. It can trigger impulse control problems such as compulsive gambling, shopping or hypersexuality, and in restless legs it can cause augmentation, where symptoms creep earlier in the day. Hallucinations are possible, more so in older adults. It is broken down by the liver enzyme CYP1A2, so ciprofloxacin raises its levels while smoking lowers them, and dopamine blocking drugs cancel its benefit.

A case report documented serotonin syndrome in a Parkinson's disease patient taking ropinirole chronically who then began duloxetine (serotonin-norepinephrine reuptake inhibitor) while continuing rasagiline (monoamine oxidase-B inhibitor) ^[5]; this represents a pharmacodynamic interaction where dopaminergic and serotonergic pathways potentiate serotonin pathway over-activation. The interaction appears to require the combination of a dopamine agonist with both an MAOI and a serotonergic antidepressant. Most other potential ropinirole interactions remain unstudied or undocumented in peer-reviewed literature. Combinations with other dopamine agonists, anticholinergics, or cardiovascular agents have not been systematically characterized.

Checking a whole stack? Run it through interactions + stacks.

Ropinirole was developed by SmithKline Beecham, a corporate predecessor of GlaxoSmithKline, as a non-ergoline dopamine agonist intended to avoid the fibrotic complications associated with the older ergot-derived agents. It was designed to stimulate dopamine receptors selectively, with a preference for the D2 and D3 subtypes, mimicking the neurotransmitter that is progressively lost in Parkinson's disease.

The United States Food and Drug Administration approved it in 1997 under the brand name Requip for the treatment of Parkinson's disease, both as early monotherapy and as an adjunct to levodopa. In 2005 it earned a further distinction as the first medication approved in the United States specifically for moderate to severe restless legs syndrome. An extended-release formulation, Requip XL, was later introduced to provide smoother, once-daily dopaminergic coverage. It has since become available as a generic.

Ropinirole is valued as a versatile dopaminergic agent that can delay the need for levodopa in early Parkinson's disease and can markedly quiet the uncomfortable sensations and urge to move that define restless legs syndrome. Its status as the first drug specifically approved for restless legs syndrome gave many sufferers a validated, evidence-based option for the first time. Clinicians appreciate that in restless legs syndrome the effective doses are far lower than those used in Parkinson's disease, which helps limit side effects.

The drug carries well-recognized cautions, including a potential for sudden sleep onset and, in a minority of patients, impulse-control problems such as compulsive gambling or shopping, and long-term use in restless legs can lead to a worsening pattern known as augmentation. Used thoughtfully and at appropriate doses, it remains a clinically important tool for two very different movement-related conditions.